Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Montefiore Medical Center, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York
Treatments:Biologic therapyHospital:Montefiore Medical Center
Drugs:Journal:Link
Date:Sep 2006

Description:

Patients: This phase II study involved 48 patients with advanced liver cancer. 73% were men, 27% women. The median age was 63 years (ranging from 25-86).

Treatment: These patients were treated with the folate analog nolatrexed dihydrochloride (ThymitaqTM).

Toxicity: All 48 patients experienced at least one adverse event. Grade 4 toxicities were stomatitis, dehydration, asthenia, nausea/vomiting, leucopenia, and thrombocytopenia. The percentage of patients experiencing grade 3/4 stomatitis was 46%.

Results: 39 of the total patients were evaluated for responses. The median overall survival for these patients was 8 months. 14% died within 3 months and 67% died within 12 months. The authors state that nolatrexed ‘demonstrated minimal activity and significant stomatitis. Hence, it does not warrant further study as a single agent for this disease.’

Correspondence: Dr. Minaxi Jhawer





Back